Barclays PLC Savara Inc Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Savara Inc stock. As of the latest transaction made, Barclays PLC holds 231,005 shares of SVRA stock, worth $753,076. This represents 0.0% of its overall portfolio holdings.

Number of Shares

231,005

Previous 231,005 -0.0%

Holding current value

$753,076

Previous $979,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$3.96 - $5.07 $645,654 - $826,633	163,044 Added 239.91%	231,005 $979,000
Q2 2024 Aug 14, 2024	SELL	$3.66 - $5.34 $37,002 - $53,987	-10,110 Reduced 12.95%	67,961 $274,000
Q1 2024 May 15, 2024	SELL	$4.19 - $5.59 $192,258 - $256,497	-45,885 Reduced 37.02%	78,071 $388,000
Q4 2023 Feb 15, 2024	BUY	$3.18 - $4.9 $343,211 - $528,847	107,928 Added 673.37%	123,956 $582,000
Q3 2023 Nov 07, 2023	BUY	$2.97 - $3.88 $2,414 - $3,154	813 Added 5.34%	16,028 $61,000
Q2 2023 Aug 03, 2023	SELL	$1.69 - $3.24 $15,781 - $30,255	-9,338 Reduced 38.03%	15,215 $49,000
Q1 2023 May 04, 2023	BUY	$1.6 - $2.82 $39,276 - $69,225	24,548 Added 490960.0%	24,553 $48,000
Q4 2021 Feb 14, 2022	SELL	$1.04 - $1.34 $7,612 - $9,808	-7,320 Reduced 99.93%	5 $0
Q3 2021 Nov 09, 2021	SELL	$1.18 - $1.64 $6,625 - $9,208	-5,615 Reduced 43.39%	7,325 $10,000
Q2 2021 Aug 13, 2021	SELL	$1.51 - $2.29 $41,253 - $62,562	-27,320 Reduced 67.86%	12,940 $22,000
Q1 2021 May 13, 2021	BUY	$1.17 - $2.33 $28,911 - $57,576	24,711 Added 158.92%	40,260 $84,000
Q4 2020 Feb 11, 2021	SELL	$1.0 - $1.47 $6,482 - $9,528	-6,482 Reduced 29.42%	15,549 $18,000
Q3 2020 Nov 12, 2020	SELL	$1.09 - $2.21 $3,841 - $7,788	-3,524 Reduced 13.79%	22,031 $24,000
Q2 2020 Aug 12, 2020	BUY	$1.8 - $3.05 $25,164 - $42,639	13,980 Added 120.78%	25,555 $63,000
Q1 2020 May 13, 2020	SELL	$1.91 - $4.08 $44,676 - $95,435	-23,391 Reduced 66.9%	11,575 $24,000
Q4 2019 Feb 10, 2020	BUY	$0.71 - $4.91 $12,126 - $83,857	17,079 Added 95.48%	34,966 $156,000
Q3 2019 Nov 14, 2019	SELL	$2.16 - $3.2 $5,611 - $8,313	-2,598 Reduced 12.68%	17,887 $47,000
Q2 2019 Aug 14, 2019	BUY	$2.37 - $11.7 $28,565 - $141,020	12,053 Added 142.94%	20,485 $49,000
Q1 2019 May 15, 2019	BUY	$6.71 - $8.6 $55,679 - $71,362	8,298 Added 6192.54%	8,432 $62,000
Q4 2018 Feb 14, 2019	SELL	$6.27 - $10.92 $89,667 - $156,166	-14,301 Reduced 99.07%	134 $1,000
Q3 2018 Nov 14, 2018	BUY	$10.49 - $12.87 $132,090 - $162,059	12,592 Added 683.23%	14,435 $161,000
Q2 2018 Aug 14, 2018	SELL	$8.55 - $13.76 $119,375 - $192,117	-13,962 Reduced 88.34%	1,843 $21,000
Q1 2018 May 15, 2018	SELL	$8.99 - $14.95 $80,011 - $133,055	-8,900 Reduced 36.03%	15,805 $145,000
Q4 2017 Feb 14, 2018	BUY	$8.26 - $16.76 $204,022 - $413,972	24,700 Added 494000.0%	24,705 $367,000
Q3 2017 Nov 14, 2017	BUY	$5.1 - $9.55 $25 - $47	5	5 $0

Others Institutions Holding SVRA

# of Institutions

129

Shares Held

158M

Call Options Held

67.6K

Put Options Held

29.4K

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $372M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account